High-Flow Nasal Cannula for Post-Cardiac Surgery Patients
Trial Summary
What is the purpose of this trial?
The purpose of this study is to compare reintubation rates and outcomes of patients treated with high-flow nasal canula oxygen therapy (HFNC) and patients treated with provider choice of standard care.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment High-Flow Nasal Cannula for Post-Cardiac Surgery Patients?
Research shows that high-flow nasal cannula (HFNC) oxygen therapy is widely used and effective in patients after cardiothoracic surgery, providing better oxygen delivery compared to conventional methods. It is also used safely in various hospital settings, including outside intensive care units, indicating its versatility and potential benefits for post-surgery patients.12345
How is high-flow nasal cannula treatment different from other treatments for post-cardiac surgery patients?
Research Team
Robert E Freundlich, MD
Principal Investigator
Vanderbilt University Medical Center
Eligibility Criteria
This trial is for adults over 18 who've had heart or thoracic aorta surgery lasting at least 3 hours and are in the Vanderbilt Cardiovascular Intensive Care Unit. They must be intubated upon ICU arrival with plans to remove the breathing tube later.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either high-flow nasal cannula oxygen therapy or provider choice of standard care post-extubation
Follow-up
Participants are monitored for reintubation and other outcomes until hospital discharge
Treatment Details
Interventions
- Provider choice standard care order set
- Recommendation for high flow nasal cannula oxygen therapy order set
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vanderbilt University Medical Center
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator